Hennion & Walsh Asset Management Inc. Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Hennion & Walsh Asset Management Inc. boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 48.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,106 shares of the specialty pharmaceutical company's stock after acquiring an additional 36,279 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.22% of KalVista Pharmaceuticals worth $1,282,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC boosted its stake in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after buying an additional 1,319 shares during the period. Legal & General Group Plc raised its position in shares of KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after acquiring an additional 1,494 shares in the last quarter. Rhumbline Advisers raised its position in shares of KalVista Pharmaceuticals by 3.4% during the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after acquiring an additional 1,762 shares in the last quarter. AlphaQuest LLC raised its position in shares of KalVista Pharmaceuticals by 17.1% during the 4th quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after acquiring an additional 3,767 shares in the last quarter.

KalVista Pharmaceuticals Trading Up 4.1%

NASDAQ:KALV opened at $14.36 on Friday. The firm has a market cap of $713.92 million, a P/E ratio of -3.95 and a beta of 0.05. The stock's 50 day simple moving average is $12.07 and its 200-day simple moving average is $10.60. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 3,808 shares of the company's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $45,086.72. Following the completion of the transaction, the chief executive officer now directly owns 293,367 shares in the company, valued at approximately $3,473,465.28. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the purchase, the insider now directly owns 5,303,985 shares of the company's stock, valued at approximately $49,963,538.70. The trade was a 0.47% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 8,730 shares of company stock valued at $102,226 over the last quarter. Company insiders own 10.50% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on KALV. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Jones Trading reaffirmed a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.